Update on emerging urate-lowering therapies.

Saima Chohan, Michael A Becker

Current Opinion in Rheumatology 2009 March

PURPOSE OF REVIEW: To discuss currently available urate-lowering therapeutic options for gout in the United States and newer therapeutic initiatives in development.

RECENT FINDINGS: Currently available urate-lowering drugs include allopurinol and probenecid. These drugs are effective but are often underdosed or underutilized, and caution must be taken in patients with multiple comorbidities. Newer therapeutic agents in development include febuxostat, a nonpurine analogue xanthine oxidase inhibitor, and pegloticase, a pegylated recombinant uricase.

SUMMARY: There have been no new US Food and Drug Administration-approved urate-lowering drugs for gout in the past 40 years. Recent advances in therapeutics promise to provide the opportunity for much needed improvement in patient outcomes in this disorder.

Full text links

We have located links that may give you full text access.

Show additional links to paperHide additional links to paper

PubMed

Add to Saved Papers

Get 1-tap access

Related Resources

For the best experience, use the Read mobile app

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app